Close Menu
USTaxNews.live – Your Trusted Source for U.S. Tax & Finance Updates
  • Home
  • Audit
  • Finance
  • IRS
  • Legal
  • Tax News
  • Tax preparation
  • Tax Tips
  • USA Accounting
What's Hot

Lindsay Clancy to face a new trial in spring of 2027 over children’s killing : NPR

November 16, 2026

Novo says Wegovy lowers BMI, obesity rates in children in trial

November 16, 2026

Big-ticket holiday items may be harder to find as shipping costs rise

November 16, 2026

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated

Subscribe to USTaxNews

* indicates required

Subscribe for Tax Updates

Get the latest IRS news, tax tips, and deadlines delivered to your inbox.

style="display:none">
Facebook X (Twitter) Instagram
USTaxNews.live – Your Trusted Source for U.S. Tax & Finance Updates
  • Home
  • About Us
  • Advertise With Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
  • Home
  • Audit
  • Finance
  • IRS
  • Legal
  • Tax News
  • Tax preparation
  • Tax Tips
  • USA Accounting
USTaxNews.live – Your Trusted Source for U.S. Tax & Finance Updates
Home » Novo says Wegovy lowers BMI, obesity rates in children in trial
Finance

Novo says Wegovy lowers BMI, obesity rates in children in trial

EditorBy EditorNovember 16, 2026No Comments3 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link


Novo on Monday released full results from a late-stage trial showing its blockbuster Wegovy injection helped children ages 6 to under 12 with obesity shed weight, significantly lowering their body mass index.

Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks, with BMI falling 17.4% among children receiving the drug and rising 2.2% among those receiving a placebo. Those results assumed patients stayed on treatment during the trial. 

When evaluating all children in the study, including those who discontinued treatment, Wegovy lowered BMI by an estimated average of 16.2 percentage points more than the placebo at 68 weeks. All 167 kids in the study received lifestyle modifications throughout the trial, including a ​reduced-calorie diet and increased physical activity. 

The detailed results mark an encouraging step forward in treating childhood obesity — a chronic disease that can carry serious cardiovascular, metabolic and psychosocial consequences but has had few treatment options for younger children. When left unaddressed, childhood obesity can extend into adulthood, bringing earlier and more severe health complications.

“This is a very significant disease burden in this very young patient population,” said Dr. Andrea Traina, Novo’s medical director lead of obesity. 

In 2025, the disease affected an estimated roughly 177 million children and teens ages 5 to 19 worldwide, according to the World Obesity Federation. That figure is projected to rise to 228 million by 2040.

While Wegovy is already approved to treat obesity in children ages 12 and older, there are currently no approved medications for those under 12. The latest results offer evidence that Wegovy can potentially fill that treatment gap, safely and effectively reducing the severity of the disease in children as young as 6. 

In Novo’s trial, 85% of children started with moderate to severe obesity, which corresponds to BMI thresholds of 35 and above and 40 or higher, respectively. Nearly half already had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea.

But more than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks of the trial, assuming patients stayed on treatment. Novo initially shared that result in September.

“We are driving towards control of this chronic disease in that patient population when they are still so young and at such high risk for more advanced and accelerated disease progression because they developed it so early,” Traina said.

Novo said Wegovy’s overall safety and tolerability among children — how well patients managed the drug — were consistent with those seen in ​trials ⁠with adults. The company added that it observed no safety concerns related to growth or pubertal development in the kids. 

Still, the two-year study does not establish whether treating obesity earlier can change its long-term trajectory, or what treatment and maintenance might look like as children grow into adulthood, Traina said. 

“That is something that is still an evidence gap,” she said, pointing to the potential of future research.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Editor
  • Website

Related Posts

Big-ticket holiday items may be harder to find as shipping costs rise

November 16, 2026

Rivian, Lucid, Scout aren’t counting on Dems to restore EV incentives

November 15, 2026

Flight delays linger, but schedule improves Monday

November 15, 2026
Leave A Reply Cancel Reply

News
Finance

Novo says Wegovy lowers BMI, obesity rates in children in trial

Novo on Monday released full results from a late-stage trial showing its blockbuster Wegovy injection…

Big-ticket holiday items may be harder to find as shipping costs rise

November 16, 2026

Rivian, Lucid, Scout aren’t counting on Dems to restore EV incentives

November 15, 2026
Top Trending
IRS

IRS raises the 2027 401(k) contribution limit by $1,000 to $25,500

The 2027 contribution limit for 401(k) plans is rising to $25,500, up…

IRS

IRS updates 2027 tax brackets and raises standard deduction to $16,600

The Big Money Show analyzes the latest tax votes as Florida voters…

IRS

IRS CEO Frank Bisignano says mobile app will combat fraud and theft

IRS CEO Frank Bisignano says the agency’s new mobile app will let…

Subscribe to News

Please enable JavaScript in your browser to complete this form.
Loading

Welcome to USTaxNews.live – Your Trusted Source for U.S. Tax, Accounting, and Financial News.

At USTaxNews.live, we’re committed to delivering accurate, timely, and practical information on everything related to U.S. taxes, IRS updates, legal issues, accounting practices, and the broader financial landscape. Whether you’re a taxpayer, accountant, legal professional, or business owner, we’re here to help you stay informed and ahead of change.

Our Picks

California voters reject Prop. 40 billionaire wealth tax, CBS News projects

November 10, 2026

Mark Zuckerberg threatened to leave California over proposed billionaire tax, Meta says

October 22, 2026

California billionaire tax could leave state with less revenue, Stanford study cautions

October 19, 2026

Subscribe to Updates

Please enable JavaScript in your browser to complete this form.
Loading
  • Home
  • About Us
  • Advertise With Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2026 ustaxnews. Designed by ustaxnews.

Type above and press Enter to search. Press Esc to cancel.